16.3 Reproductive Pathology & Hormone-Related Neoplasia
Key Takeaways
- PCOS: insulin resistance and disordered gonadotropin drive → ovarian androgen excess, anovulation, unopposed estrogen (endometrial risk), polycystic morphology; treat metabolic drivers and cycle control.
- Complete mole is usually 46,XX (paternal only) with diffuse villous swelling, no fetus, very high hCG; partial mole is often 69,XXY with fetal parts. Both are gestational trophoblastic disease; choriocarcinoma is invasive trophoblastic malignancy with high hCG.
- Cervical cancer is driven by high-risk HPV E6/E7 (p53 and Rb inactivation); endometrial carcinoma type I is estrogen-related (hyperplasia pathway); ovarian tumors split surface epithelial, germ cell, and sex cord–stromal with marker patterns.
- Breast cancer risk rises with cumulative estrogen exposure; receptors ER/PR/HER2 guide therapy. BPH is DHT-sensitive periurethral hyperplasia; prostate cancer is peripheral zone adenocarcinoma with PSA context and osteoblastic mets.
- Testicular germ-cell tumors: seminoma (PLAP+, radiosensitive, homogeneous) vs nonseminoma (AFP/hCG patterns, more aggressive). Cryptorchidism raises germ-cell tumor and infertility risk.
16.3 Reproductive Pathology & Hormone-Related Neoplasia
Quick Answer: PCOS = androgen excess + anovulation + metabolic risk. Endometriosis = ectopic endometrium with cyclic pain/infertility. PID → tubal scarring → ectopic. Complete vs partial mole by karyotype and fetal tissue. HPV E6/E7 → cervical ca. Endometrial ca often estrogen-driven. Know ovarian/breast/prostate/testicular tumor buckets and markers.
This section converts physiology into disease packages. CBSE items often give a lab + morphology hint and ask for the mechanism (e.g., unopposed estrogen, HPV E7–Rb, DHT in BPH, cryptorchid germ-cell risk).
PCOS (Polycystic Ovary Syndrome)
Core pathophysiology (simplified, high-yield):
- Insulin resistance → hyperinsulinemia increases ovarian androgen production and lowers SHBG → higher free androgens.
- Altered GnRH/LH tone (often elevated LH:FSH ratio in classic teaching) supports theca androgen output.
- Androgens impair orderly folliculogenesis → chronic anovulation, oligomenorrhea, cystic follicles on ultrasound ("string of pearls"—supportive, not solely diagnostic).
- Anovulation → unopposed estrogen (no cyclic progesterone) → endometrial hyperplasia and endometrial carcinoma risk.
- Clinical: hirsutism, acne, obesity/central adiposity common, acanthosis nigricans with insulin resistance, infertility.
Differential anchors: Late-onset CAH (17-OHP), androgen-secreting tumors (rapid virilization, very high testosterone), Cushing, hyperprolactinemia, thyroid disease. Treatment themes: weight loss/exercise; combined OCPs for cycle control and SHBG rise; spironolactone for hirsutism; metformin in insulin resistance/diabetes risk; ovulation induction (letrozole/clomiphene) for fertility—exam focuses more on mechanism than regimens.
Endometriosis
Ectopic endometrial glands and stroma outside the uterus (ovaries → chocolate cysts/endometriomas, pelvic peritoneum, cul-de-sac, uterosacral ligaments). Estrogen-dependent, cyclic hemorrhage → inflammation, fibrosis, adhesions, pain (dysmenorrhea, dyspareunia), and infertility (anatomic + inflammatory).
Theories: retrograde menstruation (Sampson), coelomic metaplasia, lymphatic/vascular spread. Definitive diagnosis historically by laparoscopy; clinically recognized by symptom pattern. OCPs, progestins, GnRH agonists reduce stimulation; surgery for severe disease/fertility—again, mechanism > protocol on CBSE.
PID and Ectopic Pregnancy
Pelvic inflammatory disease usually follows ascending infection (N. gonorrhoeae, C. trachomatis, polymicrobial anaerobes). Tubal epithelial injury and ciliary damage → salpingitis, tubo-ovarian abscess risk, chronic scarring.
Ectopic pregnancy (most often tubal ampulla): fertilized ovum implants outside endometrium. Risk factors: prior PID/tubal surgery, prior ectopic, assisted reproduction, smoking, IUD in situ (pregnancy rare but if occurs, higher ectopic proportion). Presentation: amenorrhea, unilateral pain, spotting; rupture → acute abdomen and shock. hCG positive with empty uterus on ultrasound and/or inappropriate hCG rise. Pathophysiology link: impaired tubal transport from scarring.
Gestational Trophoblastic Disease
| Feature | Complete mole | Partial mole |
|---|---|---|
| Karyotype (classic) | 46,XX (usually all paternal; empty ovum + duplicated sperm) or 46,XY paternal | 69,XXY (or other triploid) maternal + paternal |
| Fetal tissue | Absent | Present (anomalous) |
| Villi | Diffuse hydropic swelling; trophoblastic hyperplasia marked | Focal hydropic change |
| hCG | Markedly elevated | Moderately elevated |
| Clinical | "Snowstorm" ultrasound, size > dates, hyperemesis, preeclampsia early, theca-lutein cysts | Less dramatic |
| Malignant risk | Higher risk of invasive mole / choriocarcinoma | Lower than complete |
Choriocarcinoma: malignant trophoblast, early hematogenous spread (lung, brain); very high hCG; responds to chemotherapy (methotrexate-based regimens historically classic). Monitor hCG after mole evacuation.
Cervical Cancer and HPV
High-risk HPV (16, 18 most tested) infects transformation zone epithelium. Viral E6 binds p53 → degradation; E7 binds Rb → frees E2F → cell cycle progression. Progression: koilocytes → CIN grades → invasive squamous cell carcinoma (or adenocarcinoma with certain types). Risk cofactors: smoking, immunosuppression, multiple partners, early coitarche, lack of screening.
Screening/prevention concept: Pap/HPV testing catches precursors; vaccination targets major oncogenic (and some low-risk wart) types. Local invasion to parametria/ureters can cause hydronephrosis—classic advanced disease death pathway in older vignettes.
Endometrial Hyperplasia and Carcinoma
Estrogen without adequate opposing progesterone drives endometrial proliferation: obesity (aromatization in fat), anovulation/PCOS, nulliparity, early menarche/late menopause, unopposed estrogen therapy, estrogen-secreting tumors (granulosa cell).
| Pathway | Features |
|---|---|
| Type I endometrioid | Hyperplasia → atypical hyperplasia → carcinoma; ER-positive; better prognosis; PTEN mutations often cited |
| Type II (e.g., serous) | Atrophic background, p53, older thin women, more aggressive |
Protective factors: combined OCPs, multiparity, progesterone exposure. Postmenopausal bleeding is carcinoma until adequately evaluated (exam heuristic).
Ovarian Tumors (High-Yield Taxonomy)
Surface epithelial (most common overall in adults)
- Serous: cystic, psammoma bodies possible; cystadenoma vs cystadenocarcinoma; most common malignant epithelial type.
- Mucinous: multiloculated, mucin; pseudomyxoma risk considerations (appendiceal primary often).
- Endometrioid: associated with endometriosis/endometrial carcinoma.
- Clear cell / Brenner: less common; Brenner has transitional-like epithelium, coffee-bean nuclei.
Risk: more ovulation (nulliparity), genetic (BRCA, Lynch); protective: OCPs, multiparity, breastfeeding (fewer lifetime ovulations).
Germ cell (younger patients)
| Tumor | Marker / pearl |
|---|---|
| Dysgerminoma | Male seminoma counterpart; LDH, PLAP; radiosensitive |
| Yolk sac (endodermal sinus) | AFP; Schiller-Duval bodies |
| Choriocarcinoma (ovarian) | hCG; cytotrophoblast + syncytiotrophoblast |
| Immature teratoma | Malignant germ cell; immature neuroepithelium graded |
| Mature cystic teratoma (dermoid) | Benign common; teeth/hair; struma ovarii (thyroid) can cause hyperthyroidism |
Sex cord–stromal
- Granulosa cell tumor: estrogen secretion → endometrial hyperplasia/bleeding; Call-Exner bodies; inhibin marker.
- Sertoli–Leydig: androgens → virilization; rare.
- Fibroma: Meigs syndrome (ovarian fibroma + ascites + pleural effusion).
Breast: Fibrocystic Change vs Cancer
Fibrocystic changes: common, hormone-related, cyclic pain/nodularity; blue-dome cysts; apocrine metaplasia; generally benign. Proliferative lesions with atypia raise risk more than nonproliferative fibrocystic change.
Breast carcinoma risk factors: age, female sex, family history/BRCA1/2, dense breasts, early menarche, late menopause, nulliparity, late first pregnancy, combined HRT, radiation, alcohol, obesity (postmenopausal aromatase).
| Receptor profile | Therapeutic implication (concept) |
|---|---|
| ER/PR positive | Hormonal therapy (tamoxifen SERM; aromatase inhibitors in postmenopausal) |
| HER2 amplified | HER2-targeted therapy (trastuzumab class) |
| Triple negative | More aggressive; chemo-based strategies; BRCA association |
Histology pearls: invasive ductal (most common); lobular (loss of E-cadherin, lines/Indian file); DCIS → microcalcifications on mammography; Paget disease of nipple (DCIS extends to epidermis).
BPH vs Prostate Cancer
| Feature | BPH | Prostate adenocarcinoma |
|---|---|---|
| Zone | Transitional / periurethral | Peripheral zone (often posterior—DRE nodule) |
| Driver | DHT-dependent hyperplasia | Multifactorial; androgens permissive |
| Symptoms | Obstructive/irritative voiding, smooth enlargement | May be asymptomatic early; nodule/induration |
| PSA | Can elevate modestly | Elevates; also free/total patterns, velocity—context required |
| Mets | Does not metastasize | Osteoblastic bone mets classic |
| Therapy theme | α1-blockers, 5α-reductase inhibitors | Surgery/radiation/androgen deprivation for advanced |
Testicular Tumors and Cryptorchidism
Cryptorchidism: failure of testicular descent; most resolve spontaneously early, but persistent undescended testes raise infertility (heat-sensitive spermatogenesis) and germ-cell tumor risk—including in the contralateral descended testis to some degree. Orchiopexy facilitates surveillance and may improve fertility potential; tumor risk not fully eliminated.
Germ-cell tumors (≈95% of testicular malignancies)
| Type | Features / markers |
|---|---|
| Seminoma | Homogeneous, fried-egg cells, PLAP, radiosensitive, better prognosis; hCG occasionally from syncytiotrophoblast elements |
| Embryonal carcinoma | Aggressive, hemorrhagic/necrotic; may raise AFP/hCG |
| Yolk sac | Children; AFP; Schiller-Duval |
| Choriocarcinoma | hCG very high; hematogenous spread early |
| Teratoma | All three germ layers; mature teratoma in post-pubertal males still considered malignant potential unlike mature ovarian dermoid |
| Mixed | Common; markers follow components |
Nonseminomatous GCT often produce AFP and/or hCG; management and prognosis differ from pure seminoma. Painless mass is the classic presentation; biopsy is not done pre-orchiectomy in standard teaching (spread risk)—orchiectomy is diagnostic/therapeutic.
Sex cord stromal tumors (Leydig cell: Reinke crystals, androgens/estrogens; Sertoli cell) are less common.
Closing Integration Map
- Anovulation + unopposed estrogen → PCOS and type I endometrial cancer risk share a pathway.
- HPV E6/E7 is the molecular sentence for cervical neoplasia.
- Mole karyotype table separates complete vs partial before you guess hCG magnitude.
- Zone anatomy separates BPH (transition) from prostate cancer (peripheral).
- Markers (hCG, AFP, PLAP, inhibin, ER/PR/HER2) are the fastest way to score tumor questions.
- Cryptorchidism links pediatric anatomy to adult oncology and infertility physiology from 16.1.
A 24-year-old woman has oligomenorrhea, hirsutism, and BMI 34. LH is relatively high compared with FSH; fasting insulin is elevated. Which mechanism best explains her increased risk of endometrial carcinoma?
Ultrasound after missed abortion shows a "snowstorm" uterus without a fetus. Karyotype of evacuated tissue is 46,XX of paternal origin only. Which diagnosis is most accurate?
A 30-year-old man has a painless testicular mass. Histology shows sheets of large cells with clear cytoplasm and central nuclei; PLAP is positive; AFP is normal; hCG is minimally elevated. Which tumor type is most likely?